ReviewFrontiers in microbiology2026
Sequential eradication of bacterial persisters: integrating phytochemical pharmacology with microenvironment-responsive delivery strategies.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial persister cells within extracellular polymeric substance (EPS) matrices drive antimicrobial tolerance and chronic infection relapse. Conventional bactericidal agents remain fundamentally inadequate against these dormant subpopulations due to their reliance on active cellular metabolism. This review proposes a mechanistically driven, multi-phase sequential strategy-comprising barrier disruption, metabolic resuscitation, and terminal eradication-executed via highly purified, plant-derived natural products and advanced delivery systems. We synthesize recent pharmacological evidence regarding the anti-biofilm mechanisms of these active monomers and their integration with microenvironment-responsive strategies. A three-phase framework is delineated. Phase I utilizes epigallocatechin gallate (EGCG) and baicalin to physically degrade the EPS architecture and antagonize quorum sensing networks. Phase II employs Astragalus polysaccharides (APS) and exogenous metabolites to restore microbicidal host immunity and reactivate bacterial central carbon metabolism. Phase III leverages this reactivated state, utilizing berberine and shikonin to induce lethal reactive oxygen species (ROS) accumulation and terminal respiratory arrest. To resolve the pharmacokinetic limitations of these phytochemicals, we conceptualize integrating stimuli-responsive delivery systems for chronologically programmed drug release triggered by biofilm microenvironmental gradients. Ultimately, this sequential "disrupt-awaken-kill" strategy offers a potent framework to eradicate recalcitrant persisters, though translating these multi-component therapies into clinical practice requires overcoming existing manufacturing and regulatory complexities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.